MyBlueDotsMeiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy MyBlueDots8 months ago01 mins TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma invests in MPM BioImpact’s new technology and virology strategy to expand early-stage opportunities and enhance the global network. Go to Source Author: Post navigation Previous: Amylyx Pharmaceuticals Announces Proposed Public Offering of Common StockNext: Yagi & Co., Ltd.: New Material “LAVATECH” Containing Lava from Mt. Fuji to Be Exhibited at Heimtextil 2025
AI and lab tests combine to predict disease risk from rare genetic variants MyBlueDots31 minutes ago 0